Pieris Current Deferred Revenue vs Common Stock Shares Outstanding Analysis

PIRS Stock

USD 10.29 0.01 0.1%

Pieris Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pieris Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pieris Pharmaceuticals is a good investment. Please check the relationship between Pieris Pharmaceuticals Current Deferred Revenue and its Common Stock Shares Outstanding accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

Current Deferred Revenue vs Common Stock Shares Outstanding

Current Deferred Revenue vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pieris Pharmaceuticals Current Deferred Revenue account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Pieris Pharmaceuticals' Current Deferred Revenue and Common Stock Shares Outstanding is -0.46. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Pieris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pieris Pharmaceuticals' Current Deferred Revenue and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Pieris Pharmaceuticals are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Current Deferred Revenue i.e., Pieris Pharmaceuticals' Current Deferred Revenue and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

-0.46

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most indicators from Pieris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.At this time, Pieris Pharmaceuticals' Issuance Of Capital Stock is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.07 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.37 in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	31.4M	25.9M	42.8M	25.4M
Depreciation And Amortization	3.7M	8.2M	1.8M	1.9M

Total Revenue Depreciation And Amortization

Pieris Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Other Assets	Net Receivables	Retained Earnings Total Equity	Short Term Investments
Total Assets		0.73	0.73	0.91	0.82	-0.9	-0.56	0.92	0.99	0.73	-0.56	0.91	0.97	0.97	0.09	0.64	0.9	0.8	0.62	0.74	0.81	0.69	0.55	0.5	-0.71	0.65
Short Long Term Debt Total	0.73		0.58	0.64	0.77	-0.67	-0.65	0.66	0.71	0.86	-0.76	0.7	0.64	0.73	0.55	0.78	0.67	0.77	0.53	0.63	0.57	0.6	0.52	0.48	-0.73	0.48
Other Current Liab	0.73	0.58		0.74	0.76	-0.77	-0.81	0.78	0.71	0.85	-0.47	0.68	0.64	0.74	-0.1	0.82	0.59	0.77	0.73	0.64	0.71	0.7	0.56	0.21	-0.86	0.28
Total Current Liabilities	0.91	0.64	0.74		0.65	-0.82	-0.61	0.8	0.89	0.69	-0.5	0.85	0.93	0.93	0.12	0.62	0.89	0.64	0.48	0.9	0.67	0.59	0.37	0.63	-0.71	0.68
Total Stockholder Equity	0.82	0.77	0.76	0.65		-0.82	-0.68	0.84	0.82	0.78	-0.67	0.73	0.67	0.84	0.17	0.76	0.68	1.0	0.66	0.49	0.86	0.65	0.56	0.2	-0.79	0.44
Net Debt	-0.9	-0.67	-0.77	-0.82	-0.82		0.48	-0.98	-0.92	-0.65	0.52	-0.75	-0.84	-0.89	-0.16	-0.58	-0.75	-0.8	-0.5	-0.63	-0.71	-0.54	-0.46	-0.24	0.65	-0.39
Retained Earnings	-0.56	-0.65	-0.81	-0.61	-0.68	0.48		-0.51	-0.49	-0.89	0.62	-0.68	-0.46	-0.62	-0.01	-0.93	-0.57	-0.72	-0.82	-0.63	-0.64	-0.82	-0.69	-0.42	0.97	-0.29
Cash	0.92	0.66	0.78	0.8	0.84	-0.98	-0.51		0.93	0.67	-0.53	0.78	0.87	0.89	0.09	0.59	0.75	0.81	0.59	0.59	0.76	0.63	0.56	0.23	-0.68	0.36
Cash And Short Term Investments	0.99	0.71	0.71	0.89	0.82	-0.92	-0.49	0.93		0.68	-0.54	0.88	0.95	0.97	0.09	0.59	0.9	0.8	0.52	0.74	0.77	0.59	0.46	0.43	-0.65	0.68
Common Stock Total Equity	0.73	0.86	0.85	0.69	0.78	-0.65	-0.89	0.67	0.68		-0.64	0.75	0.63	0.73	0.21	0.97	0.66	0.81	0.79	0.71	0.69	0.81	0.66	0.48	-0.93	0.39
Common Stock Shares Outstanding	-0.56	-0.76	-0.47	-0.5	-0.67	0.52	0.62	-0.53	-0.54	-0.64		-0.51	-0.46	-0.58	-0.46	-0.68	-0.47	-0.67	-0.39	-0.46	-0.46	-0.43	-0.36	-0.34	0.63	-0.33
Non Current Liabilities Total	0.91	0.7	0.68	0.85	0.73	-0.75	-0.68	0.78	0.88	0.75	-0.51		0.9	0.92	-0.05	0.7	0.97	0.74	0.74	0.8	0.79	0.82	0.68	0.61	-0.77	0.68
Total Liab	0.97	0.64	0.64	0.93	0.67	-0.84	-0.46	0.87	0.95	0.63	-0.46	0.9		0.93	0.05	0.53	0.91	0.64	0.54	0.77	0.71	0.64	0.49	0.57	-0.62	0.68
Total Current Assets	0.97	0.73	0.74	0.93	0.84	-0.89	-0.62	0.89	0.97	0.73	-0.58	0.92	0.93		0.11	0.66	0.93	0.83	0.56	0.8	0.8	0.64	0.48	0.51	-0.74	0.72
Short Term Debt	0.09	0.55	-0.1	0.12	0.17	-0.16	-0.01	0.09	0.09	0.21	-0.46	-0.05	0.05	0.11		0.18	0.03	0.16	-0.24	0.16	-0.05	-0.13	-0.21	0.34	-0.08	0.04
Common Stock	0.64	0.78	0.82	0.62	0.76	-0.58	-0.93	0.59	0.59	0.97	-0.68	0.7	0.53	0.66	0.18		0.6	0.8	0.78	0.68	0.65	0.79	0.64	0.46	-0.94	0.35
Other Liab	0.9	0.67	0.59	0.89	0.68	-0.75	-0.57	0.75	0.9	0.66	-0.47	0.97	0.91	0.93	0.03	0.6		0.67	0.56	0.85	0.71	0.67	0.52	0.65	-0.67	0.78
Net Tangible Assets	0.8	0.77	0.77	0.64	1.0	-0.8	-0.72	0.81	0.8	0.81	-0.67	0.74	0.64	0.83	0.16	0.8	0.67		0.68	0.5	0.86	0.67	0.57	0.22	-0.82	0.43
Property Plant And Equipment Net	0.62	0.53	0.73	0.48	0.66	-0.5	-0.82	0.59	0.52	0.79	-0.39	0.74	0.54	0.56	-0.24	0.78	0.56	0.68		0.41	0.74	0.97	0.91	0.3	-0.85	0.16
Current Deferred Revenue	0.74	0.63	0.64	0.9	0.49	-0.63	-0.63	0.59	0.74	0.71	-0.46	0.8	0.77	0.8	0.16	0.68	0.85	0.5	0.41		0.46	0.54	0.31	0.75	-0.67	0.7
Accounts Payable	0.81	0.57	0.71	0.67	0.86	-0.71	-0.64	0.76	0.77	0.69	-0.46	0.79	0.71	0.8	-0.05	0.65	0.71	0.86	0.74	0.46		0.76	0.53	0.38	-0.73	0.46
Non Current Assets Total	0.69	0.6	0.7	0.59	0.65	-0.54	-0.82	0.63	0.59	0.81	-0.43	0.82	0.64	0.64	-0.13	0.79	0.67	0.67	0.97	0.54	0.76		0.88	0.49	-0.86	0.26
Other Assets	0.55	0.52	0.56	0.37	0.56	-0.46	-0.69	0.56	0.46	0.66	-0.36	0.68	0.49	0.48	-0.21	0.64	0.52	0.57	0.91	0.31	0.53	0.88		0.15	-0.74	0.07
Net Receivables	0.5	0.48	0.21	0.63	0.2	-0.24	-0.42	0.23	0.43	0.48	-0.34	0.61	0.57	0.51	0.34	0.46	0.65	0.22	0.3	0.75	0.38	0.49	0.15		-0.43	0.61
Retained Earnings Total Equity	-0.71	-0.73	-0.86	-0.71	-0.79	0.65	0.97	-0.68	-0.65	-0.93	0.63	-0.77	-0.62	-0.74	-0.08	-0.94	-0.67	-0.82	-0.85	-0.67	-0.73	-0.86	-0.74	-0.43		-0.34
Short Term Investments	0.65	0.48	0.28	0.68	0.44	-0.39	-0.29	0.36	0.68	0.39	-0.33	0.68	0.68	0.72	0.04	0.35	0.78	0.43	0.16	0.7	0.46	0.26	0.07	0.61	-0.34

Click cells to compare fundamentals

Pieris Pharmaceuticals Account Relationship Matchups

Pieris Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Other Current Liab	5.0M	5.5M	15.8M	10.7M	8.6M	5.7M
Total Current Liabilities	27.0M	22.1M	50.6M	36.6M	11.9M	23.7M
Total Stockholder Equity	51.4M	31.0M	50.8M	27.9M	26.8M	28.8M
Net Debt	(46.0M)	(53.5M)	(103.9M)	(25.5M)	(17.4M)	(18.3M)
Retained Earnings	(174.2M)	(211.4M)	(257.1M)	(290.4M)	(315.0M)	(299.2M)
Cash	62.3M	70.4M	117.8M	38.6M	17.4M	16.5M
Cash And Short Term Investments	104.2M	70.4M	117.8M	59.2M	26.4M	25.0M
Common Stock Total Equity	54K	55K	56K	72K	82.8K	42.7K
Common Stock Shares Outstanding	632.8K	681.0K	806.8K	927.2K	1.1M	1.4M
Liabilities And Stockholders Equity	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Non Current Liabilities Total	62.7M	51.8M	52.2M	31.0M	35.6M	30.4M
Total Liab	89.7M	74.0M	102.8M	67.6M	11.9M	11.3M
Total Current Assets	115.0M	75.7M	127.6M	73.4M	38.7M	68.3M
Common Stock	55K	56K	72K	74K	98K	53.4K
Other Liab	47.3M	35.9M	38.4M	18.7M	21.5M	26.7M
Net Tangible Assets	51.4M	31.0M	50.8M	27.9M	32.1M	31.6M
Property Plant And Equipment Net	22.9M	26.0M	23.0M	20.7M	23.8M	12.2M
Current Deferred Revenue	11.3M	12.6M	25.1M	20.8M	23.9M	17.9M
Accounts Payable	10.1M	3.0M	8.6M	4.2M	3.4M	4.0M
Non Current Assets Total	26.1M	29.3M	25.9M	22.1M	25.4M	14.6M
Other Assets	910K	3.1M	7.2M	2.9M	3.3M	1.8M
Net Receivables	6.8M	1.7M	3.3M	5.8M	6.0M	4.4M
Retained Earnings Total Equity	(147.1M)	(174.2M)	(211.4M)	(257.1M)	(231.4M)	(219.9M)
Short Term Investments	34.8M	53.2M	41.9M	20.5M	9.0M	15.9M
Capital Surpluse	189.9M	227.5M	242.7M	307.0M	353.0M	370.7M
Other Current Assets	4.1M	3.6M	6.5M	8.4M	6.3M	4.3M
Other Stockholder Equity	227.5M	242.7M	307.0M	318.5M	341.6M	214.7M
Property Plant And Equipment Gross	22.9M	22.0M	23.0M	20.7M	23.8M	25.0M
Accumulated Other Comprehensive Income	(2.0M)	(295K)	829K	(254K)	28K	29.4K
Non Current Liabilities Other	27K	62.7M	6K	52.2M	60.1M	63.1M
Property Plant Equipment	19.5M	26.0M	23.0M	20.7M	23.8M	25.0M
Non Currrent Assets Other	3.1M	3.3M	2.9M	1.4M	1.6M	1.7M
Net Invested Capital	51.4M	31.0M	50.8M	27.9M	32.1M	39.0M
Net Working Capital	88.0M	53.6M	77.1M	36.8M	33.2M	51.6M
Capital Stock	55K	56K	72K	74K	85.1K	68.4K

Pair Trading with Pieris Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pieris Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pieris Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Pieris Stock

0.71	EGRX	Eagle Pharmaceuticals Upward Rally	Pair Corr
0.88	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.62	JNJ	Johnson Johnson Financial Report 18th of July 2024	Pair Corr

Moving against Pieris Stock

0.82	PAHC	Phibro Animal Health Fiscal Year End 4th of September 2024	Pair Corr
0.78	DCPH	Deciphera Pharmaceuticals	Pair Corr
0.77	MAIA	MAIA Biotechnology	Pair Corr
0.69	INCR	INC Research Holdings	Pair Corr
0.66	AMGN	Amgen Inc	Pair Corr

The ability to find closely correlated positions to Pieris Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pieris Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pieris Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pieris Pharmaceuticals to buy it.

The correlation of Pieris Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pieris Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pieris Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Pieris Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC